You are here

Ranked: Which Areas Receive the Most Pharma R&D?

Published

2 hours ago

on

July 31, 2025

| 14 views

-->

By

Julia Wendling

Graphics & Design

  • Lebon Siu
  • Twitter
  • Facebook
  • LinkedIn
  • Reddit
  • Pinterest
  • Email

Ranked: Which Areas Receive the Most Pharma R&D?

The pharmaceutical industry has made enormous strides in treating—and even curing—a wide range of diseases and conditions. A key driver behind this progress? Billions in funding fueling research and development (R&D) at the cutting edge.

This visualization, created in partnership with Inigo Insurance, highlights which therapeutic areas currently have the largest number of drugs in development, using data from Citeline.

The Rapid Expansion of Drug Development

The global R&D pipeline has surged over the past two decades. In 2001, just 5,995 drugs were in the pipeline. Today, that number has soared to 23,875.

Leading the pack is Pfizer, with 271 drugs in development, followed by Roche (261), Novartis (254), AstraZeneca (241), and Sanofi (233). Pharma giant Eli Lilly ranks seventh with 224 drugs.

Of the nearly 24,000 drugs in the pipeline, about half (12,704) remain in the preclinical stage, while 1,568 are projected to launch in 2025.

Where Is the Most R&D Happening?

The biggest focus area is oncology, which accounts for 9,476 drugs—roughly 40% of the total pipeline. Neurological drugs follow at 3,868, while metabolic drugs, boosted by the weight-loss drug boom, total 3,314.

Therapeutic Area Number of drugs
Oncology 9476
Neurology 3868
Metabolic 3314
Infectious Disease 2879
Musculoskeletal 2157
Immunology 1469
Dermatology 1327
Sensory 1312
Cardiology 1207
Respiratory 1172
Genitourinary 885
Hematology 811
Hormonal 273
Parasitology 109
Rare diseases 7721

Surprisingly, despite being the leading cause of death in the U.S., cardiovascular drugs rank ninth, with just 1,207 drugs in development.

Meanwhile, rare diseases represent another major focus, with 7,721 drugs in progress. Companies like Novartis and Bristol Myers Squibb are leading this charge, dedicating more than half of their pipelines to rare disease treatments—132 drugs (52%) and 115 drugs (50.2%), respectively.

The Future of Pharma Breakthroughs

Pharma R&D doesn’t always align with the biggest health burdens. Instead, it follows the intersection of scientific breakthroughs, patient demand, and market opportunity—a dynamic that will continue to shape the next wave of innovation.

Explore Inigo’s Hub.

More from Inigo

  • Healthcare4 hours ago

    The $5.6T Pharmaceutical Industry in One Chart

    Pharma giants don’t just make medicine—they shape the future of healthcare. Who are the world’s major players?

  • Crime3 weeks ago

    6 Fraud Trends Reshaping Risk in 2025

    The fraud and financial crime landscapes are evolving rapidly. What are the key threats shaping risk in 2025?

  • Cryptocurrency3 weeks ago

    Ranked: The 10 Biggest Digital Heists

    Some of the largest digital heists didn’t rely on brute-force hacking, they exploited the weakest link in security: human trust.

  • Crime3 weeks ago

    The Most Costly Financial Crimes in 2024

    As cybersecurity threats escalate, which financial crimes are causing the most harm? The FBI has the data.

  • Crime4 weeks ago

    Mapped: U.S. Financial Crime Activity by State

    Suspicious activity has been rising in the U.S., but is it spread evenly throughout all 50 states? Certainly not.

  • Crime4 weeks ago

    Ranked: America’s Most Common Financial Crimes

    As technology and AI become more widespread, fraud and other suspicious activity are rising across America. Which types are the most common?

  • Economy4 weeks ago

    Tracking the $3.1 Trillion Financial Crime Pandemic

    From money laundering to fraud, financial crime acts as a drain on the economy, totaling an incredible $3.1 trillion.

  • Politics2 months ago

    Which Types of Government Rule the World?

    Over half the global population is ruled by non-centrist types of government, including autocracies and left or right wing parties.

  • Politics2 months ago

    Breaking Down the $524 Billion Investment Needed to Rebuild Ukraine

    Ukraine will require an estimated $524B over the next decade to recover from the Russia-Ukraine war. Which sectors have been most impacted?

  • Politics2 months ago

    Are Tariffs Causing U.S. Inflation Fears?

    Amid tariff increases, consumers’ expectations for U.S. inflation in the next five years have reached their highest level since March 1991.

  • Politics3 months ago

    Ranked: Executive Orders by President in the First 100 Days

    In his first 100 days, President Trump has issued far more executive orders than any other president in history.

Subscribe

Please enable JavaScript in your browser to complete this form.Join the 375,000+ subscribers who receive our daily email *Sign Up